The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > COMMENTARY
COMMENTARY
-
Pressure Mounting for Additional NHI Price Cut for Long-listed Drugs
December 12, 2011
-
“Drug Discovery Support Organization” Faces Doubts: Can It Pick Winners?
November 28, 2011
-
Perpetuation of Premium for New Drug Development Faces Hurdles
November 14, 2011
-
Further Research Needed to Advance the Use of Regulatory Science in Regulatory Affairs
November 14, 2011
-
Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
October 19, 2011
-
Pinning Hope on Academia in Seeking a Radical Cure for AD
October 10, 2011
-
New Ideas Needed to Address “Insurance Lag” for GE Drug Makers That Submit Applications Based on Info. in Public Domain
October 3, 2011
-
Discussions on Amendment of PAL Now in Final Stages
October 3, 2011
-
Korosho Revises GL for Drafting, Distributing Drug Safety Information
September 5, 2011
-
Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
August 29, 2011
-
Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
August 8, 2011
-
Current Promising Drug Candidates with a New Mode of Action
August 8, 2011
-
Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System
July 18, 2011
-
Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
July 4, 2011
-
Era of Competition Dawns in Market for AD Treatments
June 27, 2011
-
Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
June 20, 2011
-
Return to Full-bore Growth Strategy Risky for Taiyo Pharm
June 13, 2011
-
Why the Same Mistake Repeated? -MSD's Promotion Code Violations
June 6, 2011
-
GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
June 6, 2011
-
Effects of Changes to Accelerate Approval to Be Seen from November
May 30, 2011
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…